Investigational Drug Information for GDC-0349
✉ Email this page to a colleague
What is the drug development status for GDC-0349?
GDC-0349 is an investigational drug.
There have been 184 clinical trials for GDC-0349.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 8th 2013.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.
There are twenty-six US patents protecting this investigational drug and two hundred and twenty-four international patents.
Summary for GDC-0349
| US Patents | 26 |
| International Patents | 224 |
| US Patent Applications | 106 |
| WIPO Patent Applications | 92 |
| Japanese Patent Applications | 26 |
| Clinical Trial Progress | Phase 3 (2013-01-08) |
| Vendors | 36 |
Recent Clinical Trials for GDC-0349
| Title | Sponsor | Phase |
|---|---|---|
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1 |
| Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | Kazia Therapeutics Limited | Phase 2 |
Clinical Trial Summary for GDC-0349
Top disease conditions for GDC-0349
Top clinical trial sponsors for GDC-0349
US Patents for GDC-0349
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| GDC-0349 | See Plans and Pricing | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) | See Plans and Pricing |
| GDC-0349 | See Plans and Pricing | mTORC1 inhibitors | The Regents of the University of California (Oakland, CA) | See Plans and Pricing |
| GDC-0349 | See Plans and Pricing | Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) | See Plans and Pricing |
| GDC-0349 | See Plans and Pricing | 1,2-dithiolane and dithiol compounds useful in treating mutant EGFR-mediated diseases and conditions | SABILA BIOSCIENCES LLC (New City, NY) | See Plans and Pricing |
| GDC-0349 | See Plans and Pricing | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (South San Francisco, CA) | See Plans and Pricing |
| GDC-0349 | See Plans and Pricing | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases | ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN) | See Plans and Pricing |
| GDC-0349 | See Plans and Pricing | Quinolone derivatives as FGFR inhibitors | Principia Biopharma, Inc. (South San Francisco, CA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for GDC-0349
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| GDC-0349 | Australia | AU2016232923 | 2035-03-19 | See Plans and Pricing |
| GDC-0349 | Australia | AU2017286654 | 2035-03-19 | See Plans and Pricing |
| GDC-0349 | Australia | AU2020277128 | 2035-03-19 | See Plans and Pricing |
| GDC-0349 | Brazil | BR112017019790 | 2035-03-19 | See Plans and Pricing |
| GDC-0349 | Canada | CA2980016 | 2035-03-19 | See Plans and Pricing |
| GDC-0349 | Canada | CA3027506 | 2035-03-19 | See Plans and Pricing |
| GDC-0349 | China | CN106146508 | 2035-03-19 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
